Accord enters Europe as Coherus stays quiet

Accord Healthcare has capitalised on its market-leading European Commission approval for Pelgraz (pegfilgrastim) by making “meaningful sales” of the biosimilar neutropenia treatment in Germany within two days of launching. A trade introduction of Pelgraz in the UK is also underway, a company spokesperson told Generics bulletin.